Summary
79 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 60 EUR is left as net profit.
- Revenue grew by 30% a year over the last 3 years.
- It earns 25,402 EUR a year on every 100 EUR of invested capital.
- It holds more cash than debt: 135.7M € against 6.35M €.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 3.1 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 30% a year.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 2.5 EUR
- Research and development 24 EUR
- Sales and administration 34 EUR
- Taxes and other -21 EUR
- Net profit 60 EUR
Net profit, industry median (Biotechnology) -7.3 EUR
Out of every 100 EUR of revenue, 60 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 11
- Sell 2
No analyst has published a price target.
19% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- United States 97%
- Europe 2.8%
United States brings in 97% of revenue.
Segments in detail